Skip to main content

A Detailed Examination of Practice Pressures and Desired Interaction with Pharma Manufacturers

Oncology is — and will continue to be for the foreseeable future — pharma’s powerhouse. In its latest edition of World Preview 2016, Outlook to 2022, Evaluate Pharma ® predicts that oncology will remain the largest segment in 2022 with an expected annual growth of 12.5% per year, reaching $190.0bn in sales in 2022 (see table). In 2015, oncology products accounted for 10.7% of worldwide market share (twice the share of the second-place therapeutic class, anti-diabetics); by 2022, the oncology share could grow to 16.3% of worldwide sales, nearly 3 times the share of anti-diabetics.

Hit the "download" button below to read the full article.